Stopping GLP-1 drugs can quickly erase cardiovascular benefits – BioNews Central Stopping or interrupting GLP-1 drugs for six months or more in type 2 diabetes patients raises the risk of major cardiovascular events by up to 22%, undoing previous benefits. ...

Stopping or interrupting #GLP1Drugs for six months or more in #Type2Diabetes patients raises the risk of major #CardiovascularEvents by up to 22%, undoing previous benefits. 
#GLP1 #GLP1Medications #CardiovascularRisk

Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of ran... Background The potential benefits and risks of combination therapy with sodium-glucose co-transporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus monotherap...

#CombinationTherapy with SGLT-2 inhibitors and GLP-1 receptor agonists improves heart and #MetabolicOutcomes in type 2 #diabetes, reducing #HeartFailure #hospitalizations and major #CardiovascularEvents, with some increased GI side effects. #Diabetes dmsjournal.biomedcentral.com/articles/10....